2017 Press Releases

March 08, 2017 at 11:20 a.m. ETIdera Pharmaceuticals, Inc. at Cowen and Company Health Care Conference
Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
May 04, 2017Idera Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate UpdateRead MoreApr 18, 2017Idera Pharmaceuticals Announces Organizational UpdateRead MoreApr 11, 2017Idera Pharmaceuticals Advances Investigational Treatment – Intratumoral IMO-2125 in Combination with Ipilimumab - for Unmet Need in Anti-PD-1 Refractory Metastatic MelanomaRead MoreApr 05, 2017Idera Pharmaceuticals Presents Clinical Translational and Pre-Clinical Data from IMO-2125 Development Program at the American Association for Cancer Research (AACR) 2017 Annual MeetingRead MoreMar 15, 2017Idera Pharmaceuticals Reports Fourth Quarter and Year End 2016 Financial Results and Provides Corporate UpdateRead MoreMar 02, 2017Idera to Present at the 37th Annual Cowen and Company Health Care ConferenceRead MoreFeb 24, 2017Idera Pharmaceuticals Presents Update from Ongoing Phase 1 Dose Escalation Clinical Trial of Intratumoral IMO-2125 in Combination with Ipilimumab in Metastatic Melanoma Patients Refractory to Anti-PD-1 Treatment at the 2017 ASCO-SITC Clinical Immuno-Oncology SymposiumRead MoreFeb 06, 2017Idera Announces Appointment of Jonathan Yingling, Ph.D. as Senior Vice President of Early DevelopmentRead MoreJan 04, 2017Idera to Present at the 35th Annual J.P. Morgan Healthcare ConferenceRead More